Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer

医学 贝伐单抗 西妥昔单抗 伊立替康 肿瘤科 结直肠癌 临床终点 内科学 原发性肿瘤 奥沙利铂 癌症 不利影响 疾病 化疗 临床试验 转移
作者
Matthew Snyder,Sal Bottiglieri,Khaldoun Almhanna
出处
期刊:Reviews on Recent Clinical Trials [Bentham Science Publishers]
卷期号:13 (2): 139-149 被引量:24
标识
DOI:10.2174/1574887113666180328104109
摘要

Background: Colorectal cancer is one of the most common malignancies in the United States, with a large proportion of patients presenting with metastatic disease or developing a recurrence. Systemic chemotherapy is the mainstay of therapy in this setting. There is a clear benefit in the addition of bevacizumab or cetuximab (for rat sarcoma [RAS] wild type tumors) to oxaliplatin- and irinotecan-based regimens which can be considered for first-line therapy. However, many significant questions remain as to which agent reflects best practice. Objective: Our review aimed to elucidate the benefit of adding bevacizumab and cetuximab to initial therapy for metastatic colorectal cancer based on primary tumor location and a variety of other disease- and patient-related factors, addressing the paucity of evidence that currently exists in this area and contributing to current literature and clinical practices. Methods: The primary endpoints of the study were first Progression-Free Survival (PFS) and Overall Survival (OS). Secondary endpoints included best response to first- and second-line therapies, Treatment- Related Adverse Events (TRAEs), second PFS, cost of therapy, and an assessment of other patient- and disease-related factors affecting PFS and OS. Results: While there were trends towards improved OS in patients with left-sided primary tumors (n=57) compared to those with right-sided disease (n=23), there were no significant differences between the two groups in either primary endpoint. While no differences were found for patients with left- or right- sided tumors stratified by add-on agent, these analyses were limited by the small number of patients receiving cetuximab with first-line therapy (n=4). However, the bevacizumab cohort (n=76) was sizable enough to provide ample data and produce clinically relevant results. Add-on therapy with bevacizumab in our study achieved impressive survival outcomes in both left-sided (median first PFS = 13 months, 95% CI 11-15 months; median OS = 37 months, 95% CI 21-53 months) and right-sided (median first PFS = 13 months, 95% CI 9-17 months; median OS = 37 months, 95% CI 22-52 months) disease. Conclusion: These results raised questions regarding the true significance of primary tumor location when selecting bevacizumab or cetuximab for first-line therapy, particularly the current thought of using cetuximab for left-sided tumors. While the superiority of bevacizumab over cetuximab in rightsided disease remained evident upon comparison of our analysis with historical controls, survival outcomes with the agent in our analysis appeared to be similar to that of cetuximab in CRYSTAL, FIRE- 3, and CALGB/SWOG 80405 in left-sided disease. Further study is required to determine if bevacizumab truly does produce similar outcomes to cetuximab in left-sided primary tumors. Keywords: Bevacizumab, cetuximab, left-sided tumors, metastatic colorectal cancer, primary tumor location, right-sided tumors, targeted therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小谢完成签到,获得积分10
1秒前
lemongulf完成签到 ,获得积分10
1秒前
1秒前
王小西完成签到,获得积分10
2秒前
zzx完成签到,获得积分10
2秒前
量子星尘发布了新的文献求助50
5秒前
学术乞丐发布了新的文献求助10
8秒前
万能图书馆应助怡然问晴采纳,获得10
8秒前
Akim应助体贴凌柏采纳,获得10
9秒前
zyq完成签到,获得积分10
10秒前
西瓜完成签到,获得积分10
11秒前
xshzhou完成签到,获得积分10
13秒前
苗条白枫完成签到 ,获得积分10
14秒前
一棵草完成签到,获得积分10
14秒前
内向的跳跳糖完成签到,获得积分10
14秒前
遇见飞儿完成签到,获得积分0
14秒前
cream完成签到,获得积分20
15秒前
15秒前
小薛完成签到,获得积分10
15秒前
16秒前
Cu_wx完成签到,获得积分10
16秒前
噜噜噜噜噜完成签到,获得积分10
18秒前
赵慧霞关注了科研通微信公众号
18秒前
炎魔之王拉格纳罗斯完成签到,获得积分10
19秒前
内向苡完成签到,获得积分10
20秒前
以筱发布了新的文献求助10
22秒前
bhkwxdxy完成签到,获得积分10
23秒前
悦耳虔纹完成签到 ,获得积分10
23秒前
xx完成签到,获得积分10
23秒前
大气灵枫完成签到,获得积分10
23秒前
妮妮完成签到,获得积分10
24秒前
26秒前
Struggle完成签到 ,获得积分10
27秒前
27秒前
秦兴虎完成签到,获得积分10
28秒前
Drew11完成签到,获得积分10
28秒前
风趣青槐完成签到,获得积分10
30秒前
科隆龙完成签到,获得积分10
31秒前
31秒前
饱满一手完成签到 ,获得积分10
31秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038303
求助须知:如何正确求助?哪些是违规求助? 3576013
关于积分的说明 11374210
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029